Drug intelligence / Profile preview

VCAP-102

Development stage: Preclinical
Lead developer: Voyager Therapeutics
Modality: Viral Vectors → Gene Addition/Replacement → Gene Therapies
Administration: Intravenous

Overview

VCAP-102 is a bioengineered adeno-associated virus (AAV) capsid, specifically an AAV9 variant, developed using an RNA-guided TRACER AAV capsid evolution platform. It is designed to overcome the blood-brain barrier (BBB) and achieve significantly increased brain tropism following intravenous administration. VCAP-102 mediates its central nervous system (CNS) gene delivery by directly binding to alkaline phosphatase (ALPL), a highly conserved brain vascular receptor, which initiates receptor-mediated transcytosis across the BBB.

Targets

ALPL (Tissue-nonspecific alkaline phosphatase)

Beyond the preview

Go deeper on VCAP-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VCAP-102.

Explore the full profile